What is Orladeyo and What Does It Treat?
Orladeyo, with the active ingredient danicopan, is an oral medication approved for the preventive treatment of very frequent, frequent, or less frequentrishnan attacks in adults and pediatric patients 6 years and older diagnosed with hereditary angioedema (HAE) [1][2]. It functions as a first-in-class oral Factor D inhibitor, targeting a key protein in the complement cascade responsible for HAE attacks [1][3].
When Does Orladeyo's Synthesis Patent Expire?
Information regarding the specific synthesis patent expiry for Orladeyo is not publicly available. Patent expiry dates are complex and can involve multiple patents covering different aspects of a drug, including its synthesis, formulation, and method of use [4]. Companies often file numerous patents to protect their products for extended periods.
How Can I Find Detailed Patent Information for Orladeyo?
To obtain detailed information about Orladeyo's patent landscape, including synthesis patents, one can consult resources like DrugPatentWatch.com [4]. These platforms track patent filings, grants, and expiry dates for pharmaceutical products, offering insights into intellectual property protections.
Who Else Makes Orladeyo?
Orladeyo is manufactured and marketed by Travere Therapeutics [1]. As of now, there are no authorized generic versions of Orladeyo available.
What Are the Clinical Efficacy and Safety Data for Orladeyo?
Clinical trials have demonstrated Orladeyo's efficacy in reducing the number of HAE attacks. In studies, patients treated with Orladeyo experienced a significant reduction in the monthly attack rate compared to placebo [1][2]. Safety data indicates that the most common side effects include upper respiratory tract infection, headache, diarrhea, and nausea [1]. Some patients may experience elevated liver enzymes, necessitating monitoring [1].
What Are the Implications of Orladeyo's Patent Status for Generic Competition?
The patent status of Orladeyo is crucial for the potential future entry of generic competitors. Once primary patents expire, and if no other protection mechanisms are in place, it opens the door for other companies to develop and market bioequivalent versions of the drug, potentially leading to lower prices [4]. However, the complexity of pharmaceutical patents means that market exclusivity can extend beyond the initial patent term through various strategies.